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Abstract 
Human melanoma susceptibility is often characterized by germline inactivating CDKN2A 
(INK4A/ARF) mutations, or mutations that activate CDK4 by preventing its binding to and 
inhibition by INK4A. We have previously shown that a single neonatal UVR dose delivered 
to mice that carry melanocyte-specific activation of Hras (TPras) increases melanoma 
penetrance from 0 to 57%. Here we report that activated Cdk4 cooperates with activated 
Hras to greatly increase susceptibility to melanoma in mice. While UVR treatment failed to 
induce melanomas in Cdk4R24C/R24C mice, it greatly increased the penetrance and 
decreased the age of onset of melanoma development in Cdk4R24C/R24C/TPras animals, 
compared to TPras alone. This increased penetrance was dependant on the threshold of 
Cdk4 activation, as Cdk4R24C/+/TPras animals did not show an increase in UVR-induced 
melanoma penetrance compared to TPras alone. In addition, Cdk4R24C/R24C/TPras mice 
invariably developed multiple primary lesions, which occurred rarely in TPras mice. These 
results indicate that germline defects abrogating the pRb pathway may enhance UVR-
induced melanoma. TPras and Cdk4R24C/R24C/TPras tumors were comparable 
histopathologically, but the latter were larger and more aggressive, and cultured cells 
derived from such melanomas were also larger and had higher levels of nuclear atypia. 
Moreover, the melanomas in Cdk4R24C/R24C/TPras mice, but not TPras mice, readily 
metastasized to regional lymph nodes. Thus it appears that in the mouse, Hras activation 
initiates UVR-induced melanoma development, while the cell cycle defect introduced by 
mutant Cdk4 contributes to tumor progression, producing larger, more aggressive, 
metastatic tumors. 
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Introduction 
In some transgenic strains of mice [Mt-Hgf/Sf (1); and TPras (2, 3)], a single erythemal 
UVR dose of 9kJ/m2 to 2-4 day old neonates, induces melanoma development with greatly 
increased penetrance compared to chronic UVR treatments to adult mice of the same 
genotype. In humans, melanoma susceptibility is often characterised by mutations of 
CDKN2A (which encodes p16INK4A and p14ARF) and CDK4. INK4A is a CDK-inhibitor that 
binds to and inhibits CDK4 (and CDK6), which otherwise phosphorylates pRb and induces 
G1-S phase progression. ARF acts through a distinct pathway involving stabilization of p53 
through abrogation of MDM2-induced p53 degradation (4). Underlining the importance of 
CDK4 in melanoma susceptibility are germline CDK4 mutations (R24C or R24H) in some 
melanoma kindreds (5, 6)  that render it resistant to INK4A inhibition. It is unclear if such 
mutations are functionally equivalent to deletion of INK4A, as other inhibitors (p15INK4B, 
p18INK4C and p19INK4D) are also capable of binding and inhibiting CDK4, and their 
interaction is also thought to be abrogated by the R24C mutation.  
Ras/Raf/MAPK pathway activation is also critical for melanoma development. The 
MAPK pathway is activated through mutation of BRAF in 62-72% of sporadic melanomas 
and by RAS mutations in about 10% (7, 8). The relationship between MAPK activation and 
UVR exposure is complex. BRAF mutations are rarely found in mucosal and acral 
melanomas (i.e. those not associated with sun-exposure) (9, 10). Interestingly, neither are 
they found commonly in areas of chronic UVR exposure (e.g. the face, where NRAS 
mutations are more likely), but are often found in melanomas from areas of intermittent 
sun exposure (e.g. the back and trunk) (10). Despite differences in specificity between Ras 
family members, mice carrying mutations either in Hras (2, 3) or Nras (11) develop 
melanoma. Further in vivo evidence for the role of Braf in melanocyte neoplasia comes 
from zebrafish, where Braf mutations induce nevus formation and cooperate with p53-
deficiency to induce melanoma (12).  
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Mice carrying specific ablation of either Ink4a (13, 14) or Arf (15)  rarely develop 
melanoma spontaneously (reviewed (16)). However melanocyte-specific activation of Hras 
on both Ink4 and Arf-null backgrounds leads to spontaneous melanoma development (17), 
but with only locally invasive, non-metastatic tumors. As an additional model for human 
melanoma, Cdk4 has also been targeted in mice, by homologous recombination to “knock 
in” the activating R24C mutation (18). These animals are prone to cancer as they age but 
do not develop melanomas unless exposed to potent carcinogens (19). Interesting inroads 
have been made into the relative roles of the pRb and p53 pathways in UVR-induced 
melanoma development in mice (17). UVR treatment increases melanoma penetrance in 
Arf-/-/Tyr-Hras but not Ink4a-/-/Tyr-Hras animals. Thus, in mice at least, germline mutations 
resulting in pRb pathway dysregulation may eliminate the melanoma-inducing effects of 
UVR. Spontaneous melanomas in Arf-/-/Tyr-Hras animals have a high degree of 
chromosomal instability, while UVR-induced lesions are cytogenetically intact except for 
frequent genomic amplification targeting Cdk6 (17). To further assess the role of the pRb 
pathway in murine melanoma development we have assessed spontaneous and UVR-
induced melanoma in Cdk4-R24C mutant mice that also carry melanocyte-specific 
activated Hras. 
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Materials and Methods 
All experiments were undertaken with the approval of the QIMR Animal ethics committee 
(approval number A98004M). 
 
Mouse strains. 
Cdk4R24C/R24C mice have been previously described (18). Tyr-Hras (G12V) transgenic mice 
(TPras) express mutant (G12V) Hras in a melanocyte-specific manner via a tyrosinase 
gene promoter/enhancer cassette (2). All mice were on a mixed SV129/C3H background. 
 
UVR treatments.  
At day 2-4, animals were irradiated with a single UVR dose of 8.15 kJ/m2 as described 
previously (3).  
 
Cell Culture and Morphology. 
Tumors were digested in 1.2 U/ml Dispase (Invitrogen, Carlsbad, CA), and cultured in 
RPMI (GIBCO, Carlsbad, CA), supplemented with 10% fetal bovine serum (CSL Limited, 
Australia). Cell lines were grown on cover-slips, and DNA and microtubules were 
examined by fluorescence microscopy as previously described (20).  
 
FACS Analysis  
Cells were fixed in 70% ethanol and stained with propidium iodide (Molecular Probes, 
Carlsbad, CA). The ploidy status was determined using the FACCalibur (BD bioscience, 
Franklin Lakes, NJ) cell sorter and data analyzed with Modfit Software (Verity, Topsham, 
ME). Ploidy status was determined by comparing the profile of diploid lymphocytes to that 
of the melanoma cell lines. 
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Immunohistochemistry (IHC). 
Paraffin-embedded sections of melanomas were dewaxed, and antigen retrieval 
performed using citrate buffer, pH 6.0. Endogenous peroxidase activity was quenched in 
3% H202 for 10 min, and sections were then washed and blocked with 10% goat serum. 
The primary antibodies were a p16 polyclonal antibody (SC-1207, Santa Cruz 
Biotechnology, Santa Cruz, CA) applied at 1:300 dilution, a p53 polyclonal antibody (CM5, 
Novocastra, UK) applied at 1:500, a tyrosinase-related protein 1 (Tyrp1, αPEP1) 
polyclonal antibody diluted 1:500 (a gift from Dr V.J. Hearing), a rabbit anti-caspase 3 
(Biocare Medical, Concord, CA) diluted 1:500 and a biotin-labeled anti-MCM7 mouse 
monoclonal diluted 1:250 (Neomarkers, Freemont, CA). Secondary detection was via an 
Envision plus detection kit (DAKO, Denmark), which was visualized using AEC plus 
(DAKO), and sections were counterstained with haematoxylin.  
 
PCR, RT-PCR and Sequencing Analysis. 
DNA and RNA were extracted using Qiagen kits (Qiagen, Germany). Cdkn2a copy number 
was assessed by multiplex PCR with exon-specific primers using Gapdh as a control 
(supplementary Fig 1). Levels of Ink4a, Arf, Cdk6 and c-Myc expression were determined 
by SYBR Green (Qiagen) real-time quantitative PCR. cDNA was made using Superscript 
ΙΙ reverse transcriptase (Invitrogen), and subsequent PCR reactions were carried out on a 
Rotorgene 3000 cycler (Corbett Research, Australia). Data was analyzed using Rotorgene 
6 software as previously described (21). β-Actin was used as a PCR control, and 
expression in melanomas and cell lines was compared to that in wild-type skin. 
Sequencing was performed using BigDye Terminator 3 methodology (ABI Prism, Foster 
City, CA) on a 3100 Genetic Analyzer (ABI Prism). Data was analyzed using SeqDoC 
software (22).  Primers were designed to amplify the entire 1709 bp Trp53 cDNA (open 
reading frame) in 3 overlapping fragments, and were located in sequences that are not 
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shared with the Trp53 pseudogene on chromosome 17. All primer sequences available 
(supplementary data Table Ι).  
 
Statistical Analysis 
The survival of mice in each treatment group was estimated using Kaplan-Meier analysis, 
and the log-rank test was used to test for pairwise differences between the groups. The 
associations between treatment and the proportion of mice that developed disease 
characteristics were tested using pairwise Fisher's exact tests or Mann-Whitney U tests. 
The statistical significance levels for all tests were adjusted for the multiple pairwise 
comparisons using the Bonferroni method.  
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Results 
Cdk4R24C/R24C/TPras mice develop multiple spontaneous and UVR-induced 
melanomas. 
We compared penetrance of melanoma at one year in Cdk4R24C/R24C, Cdk4R24C/R24C/TPras, 
Cdk4R24C/+/TPras mice, after a single neonatal UVR dose of 8.15 kJ/m2, with untreated 
mice of the same genotype as controls. Fig. 1D shows the Kaplan-Meier curve for tumor-
free mice at one year of age. Cdk4R24C/R24C mice did not develop melanoma spontaneously 
or after neonatal UVR. As reported previously (3), TPras mice developed neonatal UVR-
induced, but not spontaneous melanomas (Fig. 1D). However, 58% of mice homozygous 
for the Cdk4-R24C mutation, and also carrying the melanocyte-specific activated Hras 
(Cdk4R24C/R24C/TPras), developed melanoma spontaneously. UVR treatments increased 
the penetrance of tumor development to 83% (and from 0-40% for Cdk4R24C/+/TPras mice), 
and decreased the estimated age of onset compared to untreated animals (Fig. 1D) 
Lesions were mainly dermal melanomas. They were often multicentric, had aberrant 
nuclear features, and were usually accompanied by epidermal hyperplasia in UVR-treated 
animals (Fig. 2A). The increased melanoma susceptibility in mice carrying both activated 
Cdk4 and Hras is underlined by their increased propensity to develop multiple primary 
melanomas. All melanoma-bearing UVR-treated Cdk4R24C/R24C/TPras animals developed 
more than one primary lesion, significantly more than untreated Cdk4R24C/R24C/TPras mice 
(40%, p= 0.012, Fisher exact test, Bonferroni adjustment) or UVR-treated TPras mice 
(16%, p= 0.001)(Fig. 1A).  
 
Mice carrying activated Cdk4 and Hras develop aggressive metastatic melanomas. 
Cohorts carrying both mutant Cdk4 and Hras were also more likely than TPras animals to 
develop lymph node metastases (Fig. 1B). Metastases, defined as enlarged draining 
lymph nodes that stained for Tyrp1, were seen in 92% (12/13) of tumor-bearing UVR-
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treated Cdk4R24C/R24C/TPras; 60% (3/5) of spontaneous Cdk4R24C/R24C/TPras, and 16% 
(1/6) of UVR-treated TPras animals respectively. All metastases involved only the draining 
lymph node, with no evidence of visceral dissemination. Small numbers of scattered 
Tyrp1-positive cells were sometimes observed in the lymph nodes of melanoma-free 
TPras mice.  However mice with enlarged nodes generally had a single macrometastasis; 
these ranged in size from approximately 400-1000 cells. The Cdk4R24C/R24C/TPras (+UVR) 
cohort had a higher rate of metastatic melanoma than the TPras (+UVR) cohort (p= 0.001, 
Fisher exact test, Bonferroni adjustment). In addition to being more prone to development 
of metastases, the primary lesions on the UVR-treated Cdk4R24C/R24C/TPras were on 
average larger than those carried by the TPras animals (Fig. 1C), although the difference 
fell just short of significance (p= 0.057).  
We hypothesized that tumors in the mice carrying the Cdk4 defect may be more 
aggressive because of a cell cycle control defect introduced by pRb pathway deregulation, 
hence we examined cultured melanoma cells from various genotypes for evidence of 
mitotic defects (Fig. 3A). Nuclei in cultured TPras melanoma cells ranged from 7-18 μm in 
diameter, whereas nuclei from Cdk4R24C/R24C/TPras tumors were 20-70 μm in diameter.  
Additionally, the latter cultures had a higher proportion of multinuclear cells, and generally 
larger cytoplasmic and nuclear volume than the TPras cells. We also assessed DNA 
content in two cell lines where low melanin content permitted FACS analysis (Fig. 3B). The 
TPras cell line was diploid, while the Cdk4R24C/R24C/TPras cell line was aneuploid. To 
confirm that this difference in nuclear size was not simply an artefact of culture, we also 
measured nuclear size in tumor sections. The nuclei in tumors from TPras animals were 
smaller than those in Cdk4R24C/R24C/TPras melanomas (Mann-Whitney U test p<0.01) (Fig. 
3C, D). Interestingly, nuclei in the TPras primary tumor cells (range 2.5-15 μm) were within 
the same size range as those in corresponding cultured TPras melanoma cells (7-18 μm), 
whereas nuclei in cultured Cdk4R24C/R24C/TPras melanoma cells (20-70 μm) were 
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considerably larger than their in vivo tumor counterparts (4-20 μm). The additional 
increase in nuclear size of Cdk4R24C/R24C/TPras melanoma cells in culture presumably 
reflects their transition to aneuploidy, which did not occur in TPras cultures. 
To further assess phenotypic parameters that may explain the differences in 
aggressiveness between Cdk4R24C/R24C/TPras and TPras tumors, we scored proliferation, 
apoptosis and vascularity in melanoma sections (Fig. 2B). Tumors from UVR-treated 
Cdk4R24C/R24C/TPras mice had significantly greater blood vessel density than that of TPras 
(+UVR) tumors (Mann-Whitney U test, p<0.01), in keeping with the fact that TPras 
melanomas are small in situ lesions (Fig. 4A). Moreover, there were more proliferating 
cells in the UVR-induced Cdk4R24C/R24C/TPras melanomas than in the UVR-induced TPras 
tumors although this fell just short of significance (Mann-Whitney U test, p = 0.078) (Fig. 
4B). There was no significant difference in the level of apoptosis between any of the 
cohorts (Fig. 4C). 
 
Molecular changes in Cdk4R24C/R24C/TPras melanomas. 
Genomic PCR and real-time qRT-PCR were used to assess the relative copy number of 
Ink4a and Arf genes respectively. In addition to testing the melanomas, we also analyzed 
cell lines generated from them, to confirm that stromal contamination did not mask loss of 
Ink4a or Arf. No loss of either gene or their transcripts was seen in tumors (N=17) or cell 
lines (N=12) from mice of any cohort carrying the Cdk4-R24C mutation. We also stained 
tumor sections for Ink4a by IHC (supplementary Fig 2). Ink4a immunoreactivity was 
observed in 31/35 (89%) samples (Table Ι). 
We also stained for Trp53 protein in tumors and found that 36/56 (64%) of the 
melanomas were positive (Table Ι). However, we rarely observed Trp53 staining in 
spontaneous Cdk4R24C/R24C/TPras melanomas (2/8), whereas it was present in the majority 
of UVR-induced Cdk4R24C/R24C/TPras tumors (25/35). Trp53 reactivity was generally 
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sparse, moderately intense, nuclear staining, such as observed in the UVR-treated skin 
used as a positive control (Fig. 2C). Thus this Trp53 staining in our tumors probably 
represents upregulation of the protein in some tumor cells in response to cellular 
deregulation or damage. In some Trp53-positive tumors, staining was more intense and 
occasionally cytoplasmic. This staining seemed to be specific to the UVR-induced tumors, 
as it was observed in 11/35 (31%) Cdk4R24C/R24C/TPras (+UVR) compared to 0/8 
spontaneous Cdk4R24C/R24C/TPras melanomas. We hypothesized that such high 
expression may have been indicative of a mutant Trp53, as has been shown in other 
studies of mouse melanomas (23). However, sequencing of the entire Trp53 open reading 
frame in 7/11 of these high Trp53 expressing tumors revealed no mutations, thus the 
mode of p53 dysregulation in these lesions is unknown. It should be noted that the lack of 
staining for Ink4a or Trp53 does not necessarily mean loss of expression, as neither 
protein can be detected by IHC in unchallenged wild-type mouse skin. 
We also examined expression of c-Myc and Cdk6, which have been previously 
shown to be upregulated by gene amplification (>2-fold relative to melanocytes) in some 
mouse melanomas (17, 24). This was assessed by qRT-PCR, with results expressed 
relative to wild-type skin (normalized to a value of 1). c-Myc expression was significantly 
higher (p= 0.041, Mann-Whitney U test) in spontaneous Cdk4R24C/R24C/TPras lesions 
(mean= 1.9, N= 3) than UVR-induced melanomas of the same genotype (mean=0.892, N= 
8) (Table Ι). Neither cohort showed significant amplification of Cdk6 over wild-type levels 
(UVR-induced Cdk4R24C/R24C/TPras; mean= 0.786, N= 8, and spontaneous 
Cdk4R24C/R24C/TPras; mean= 1.13, N= 3). 
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Discussion 
It has been previously found (17) that following UVR, mice carrying a pRb pathway defect, 
together with melanocyte-specific activation of Hras (Ink4a-/-/Tyr-Hras), do not show an 
increase in melanoma development over spontaneous levels, indicating that pRb pathway 
defects may not be required for UVR-induced melanoma. Our data for Cdk4R24/+/TPras 
heterozygous mice adds some support for this conclusion since Cdk4R24/+/TPras animals 
developed UVR-induced melanoma with the same penetrance as mice carrying only 
activated Hras (TPras). This indicates that their melanoma development is being driven by 
activated Ras alone. However, when in a homozygous state, the Cdk4 mutation did 
increase melanoma penetrance in mice following UVR. Cdk4R24/R24C/TPras mice 
developed melanomas with significantly greater incidence and earlier onset than the TPras 
animals (Fig. 1D), suggesting that involvement of the pRb pathway in UVR-induced 
melanoma may depend on a particular threshold of pRb pathway deregulation. 
Involvement of pRb pathway abrogation in UVR-induced melanoma development is not 
unexpected as some studies have indicated a role for pRb in DNA repair. In vitro studies 
with Ink4a and Arf-null murine embryonic fibroblasts (25) have shown that, at least in that 
cell type, pRb pathway abrogation results in a significant diminution of DNA repair capacity 
(interestingly there was little difference between Ink4-/- and Arf-/- cells).  
The penetrance of UVR-induced melanoma in TPras transgenics on an Arf or trp53-
null background is unknown. However Arf-/-/Tyr-Hras mice (17) developed UVR-induced 
melanomas with greater penetrance than our similarly treated Cdk4R24C/R24C/TPras mice 
(80% compared to 40% at 150 days). We predict that Arf-/-/TPras (or Trp53-/-/TPras) mice 
may have an even earlier age of onset than Arf-/-/Tyr-Hras because of the higher 
expression of Hras in our TPras transgenics, compared to the Tyr-Hras transgenics of 
others (17). This would suggest that Arf-/-/TPras (or Trp53-/-/TPras) mice would develop 
melanomas with a greater penetrance and earlier onset than our Cdk4R24/R24C/TPras 
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animals, and thus a p53 pathway defect would still be more effective at inducing 
melanoma in this model. 
Another possible explanation for the difference between our study and that of 
Kannan et al, (17) is that the use of activated Cdk4 (at least in the homozygous state) 
ultimately has a different functional effect than Ink4a ablation. In Ink4a knockout mice 
other members of the same family of cyclin-dependent kinase inhibitors (i.e. Ink4b, Ink4c, 
Ink4d) may be able to compensate to some degree for Ink4a loss. In contrast, 
homozygosity for the activated Cdk4 would over-ride such inhibitor redundancy. Evidence 
for such redundancy comes from studies with mice null for another Ink4 inhibitor, Ink4c 
(19). These animals develop significantly more carcinogen-induced melanocytic lesions 
than controls, indicating that, in addition to Ink4a, Ink4c also plays a role in suppressing 
melanocyte transformation via regulation of Cdk4. This argument for inhibitory redundancy 
is supported by our results showing that the wild type copy of Cdk4 carried by our 
Cdk4R24/+/TPras cohort seems to play a role in protecting against initiation of UVR-induced 
melanoma. We found no evidence of loss of the wild type allele in the Cdk4R24/+/TPas 
melanomas (data not shown). This is to be expected if, as we suggest, the tumor 
development is primarily being driven by the activated Ras.  
Further highlighting the cooperativity between activated Cdk4 and UVR, the UVR-
treated animals more often presented with multiple primaries, and generally developed 
larger lesions than those in TPras animals although there were no obvious 
histopathological differences between spontaneous and UVR-induced melanomas from 
Cdk4R24/R24C/TPras mice. The differences in aggressiveness seem to be due to a higher 
degree of cell proliferation in tumors carrying the mutant Cdk4, as there was no significant 
difference in tumor cell apoptosis between genotypes. In addition, the Cdk4R24C/R24C/TPras 
melanomas had a significantly greater density of blood vessels than TPras lesions. 
although we suspect that this is primarily due to the fact that the tumors carrying mutant 
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Cdk4 are on average much larger than the in situ lesions which predominate in the TPras 
mice. In keeping with their aggressive phenotype, UVR-induced Cdk4R24C/R24C/TPras 
tumors had larger nuclei than those from TPras animals and their corresponding cell lines 
exhibited other evidence of mitotic defects including aneuploidy, increased nuclear size 
heterogeneity and the appearance of multinuclear cells.  
Concomitant abrogation of the pRb and p53 pathways is a hallmark of mouse 
melanomas (17, 23). We saw no evidence of loss of Ink4a in the Cdk4R24C/R24C/TPras 
tumors, as may be expected because the pRb pathway is already deregulated by the 
constitutively active Cdk4. Gain of chromosome 15, with resultant over-expression of c-
Myc, has previously been observed in spontaneous Trp53-/-/Tyr-Hras melanomas (24). 
This was not observed in Ink4a-/-/Tyr-Hras tumors (17), indicating that it may be an 
alternative method of abrogating the pRb axis, given that c-Myc over-expression alone can 
cause loss of the G1 cell cycle transition via activation of either Cdk2 or Cdk4 complexes 
(26). We observed c-Myc upregulation in some spontaneous melanomas, consistent with 
the results of Bardeesy et al. (24), indicating that high levels of c-Myc expression is 
sometimes observed in melanomas regardless of whether they are induced on a 
background of pRb or p53 pathway deficiency. Notably, this was not observed in UVR-
treated melanomas in our study, nor by Kannan et al. (17), indicating that c-Myc 
deregulation may be limited to spontaneous melanoma. 
Cdk6 amplification is another avenue of pRb pathway deregulation in mouse 
melanoma, and is a marker for UVR-induced melanoma in Arf-/-/Tyr-Hras mice, with Cdk6-
amplified tumors showing greater than 2-fold increase in expression compared to mouse 
melanocytes (17). None of our melanomas attained this level of overexpression. Thus 
Cdk6 upregulation does not appear to be a marker of UVR-induced melanoma in our 
strains, and its amplification may be specific to UVR-induced melanomas generated on Arf 
or Trp53-null backgrounds. 
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We also looked for evidence of p53 pathway inactivation but found no loss of Arf at 
the genomic or transcriptional level in any melanomas generated on the Cdk4-R24C 
background. This might be expected, as Arf is usually co-deleted with Ink4a at the Cdkn2a 
locus, and in our models there is no selective pressure for such loss as the pRb pathway is 
already inactivated by mutant Cdk4. However we often observed Trp53 expression in 
tumors that was never observed in non-treated wild-type skin and is probably due to 
cellular stress or p53 pathway deregulation.  Trp53 expression was observed more often in 
UVR-induced than in spontaneous tumors (Table Ι). High over-expression, not associated 
with Trp53 mutation, but possibly indicative of further p53 dysregulation or resistance to 
degradation, was invariably found only in UVR-induced tumors. This is consistent with 
other studies (17) indicating that in mice carrying a pRb pathway defect, deregulation of 
the p53 pathway may be involved in melanoma development, further underlining the 
significant role for p53 pathway deregulation in UVR-induced melanoma. 
In summary, we have shown that inactivation of the pRb pathway by mutant Cdk4 in 
mice also carrying melanocyte-specific Hras activation, leads to the development of 
multiple metastatic melanomas. The exposure of these mice to a single neonatal UVR 
treatment significantly increases the penetrance and decreases the age of onset of 
tumors, indicating that in this model, abrogation of the pRb pathway affects response to 
UVR. Our results are suggestive of a model where pRb pathway defects increase 
susceptibility to UVR-induced melanoma. 
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Figure legends 
Figure 1. Melanoma penetrance and phenotypic characteristics. A, Bar graph 
displaying the percent of melanoma-bearing animals that developed multiple primary 
melanomas. B, Percent of melanoma-bearing animals that developed melanoma 
metastases. C, Proportion of melanoma-bearing animals that developed lesions of over  
1 cm2 in size. D, Kaplan-Meier curve estimating the time to spontaneous and UVR-induced 
melanoma development in the various genetically modified mice. Animals that died without 
developing melanoma are represented by a black dash. There was a significant difference 
in melanoma penetrance between the UVR-treated Cdk4R24C/R24C/TPras (Cdk4R/R/TPras) 
cohort, and the UVR-treated Cdk4R24C/+/TPras (Cdk4R/+/TPras), TPras, and spontaneous 
Cdk4R24C/R24C/TPras cohorts (p<0.001, log rank test). The age of mice was defined by the 
appearance of cutaneous melanoma and additional signs of morbidity.  
 
Figure 2. Histological staining of melanoma sections. A, H&E stained section of a 
cutaneous melanoma exhibiting hyperplasia of the epidermis (left image), that was 
frequency observed in UVR-treated animals. Pigmented tumor cells were frequently 
observed in lymph nodes (centre image), and the right image shows Tyrp1-positive tumor 
cells staining red (scale bar= 0.1mm). B, Sections of melanomas stained for MCM7 (left), 
Caspase 3 (middle) and H&E (right) (scale bar= 0.1 mm), the latter image shows several 
clearly visible blood vessels containing red blood cells. C, Immunohistochemical staining 
of Trp53 in non-treated wild-type mouse skin (left) (scale bar= 0.1 mm), UVR-treated wild-
type mouse skin (middle) (scale bar= 0.1 mm) and melanoma lesion (right) (scale bar= 50 
μm). 
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Figure 3. Nuclei atypia in melanoma cells carrying mutant Cdk4. A, Representative 
images of tumor cell lines stained for DNA (Hoechst) and microtubules (α-tubulin). The 
nucleus size ranged from 7-18 μm in TPras (+UVR) cells (2 images on left) and between 
20-70 μm in Cdk4/R24C/R24C/TPras  (+UVR) cells (two images on right) (scale bar= 50 μm). 
B, The two histograms on the left show the TPras (+UVR) melanoma cell line (the first is 
cell line alone and the second is cell line spiked with lymphocytes). The two histograms on 
the right show the Cdk4/R24C/R24C/TPras  (+UVR) melanoma cell line (the second is spiked 
with lymphocytes).  The TPras (+UVR) cell line is diploid and the Cdk4/R24C/R24C/TPras  
(+UVR) cell line is aneuploid. C, Average size of nuclei in melanomas from 
Cdk4/R24C/R24C/TPras (+UV) and TPras (+UV) mice. Nuclear size was determined by 
measuring H&E stained sections. 50 cells over 5 fields from each melanoma were counted 
from the two genotypes (number of tumors counted shown in graph). D, Average percent 
of nuclei per tumor greater than 10 μm for both genotypes.  
 
Figure 4  Tumor aggressiveness in Cdk4R24C/R24C/TPras and TPras melanomas.   
Mean and standard error of the mean of (A) blood vessels per field (X200) in ten randomly 
selected fields per tumor; (B) proliferating cells (MCM7 staining) per field (X400) in ten 
randomly selected fields per tumor; (C) apoptotic cells (cleaved caspase 3 staining) per 
field (X400) in ten randomly selected fields per tumor. Mean and standard error are shown.  
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Strain  
 
Cdk6 
upreg 
c-Myc 
upreg 
Ink4a Trp53 Trp53 
upreg 
Trp53 
mutations 
TPras/Cdk4R/R   +UV
  
Melanomas 
 
Melanoma cell lines 
 
 
0%  n=8 
 
ND 
 
 
0%  n=8 
 
ND 
 
 
86%  n=29  
 
ND 
 
 
71%  n=35 
 
ND 
 
 
31%  n=35 
 
 
 
 
0% n=7 
 
0% n=1 
TPras/Cdk4R/R   -UV 
                     
Melanomas 
 
        Melanoma Cell line
 
 
0%  n=3 
 
ND 
 
 
66%  n=3 
 
ND 
 
 
78%   n=9 
 
ND 
 
 
25%  n=8 
 
ND 
 
 
0% n=8 
 
 
 
 
0% n=3 
 
ND 
TPras/Cdk4R/+   +UV 
  
Melanomas 
  
Melanoma Cell line
 
 
0%  n=1 
 
ND 
 
 
0%  n=1 
 
ND 
 
 
100%   n=5 
 
ND 
 
 
83%  n=6 
 
ND 
 
 
67%  n=6 
 
 
ND 
 
ND 
TPras   +UV 
  
Melanomas 
             
Melanoma Cell line
 
 
ND 
 
ND 
 
 
0% n=3 
 
ND 
 
 
71%  n=7 
 
ND 
 
 
57%  n=7 
 
ND 
 
 
29%  n=7 
 
 
ND 
 
ND 
 
Table Ι Molecular analysis of melanomas. Quantitative real-time PCR (qRT-PCR) 
was used to detect c-Myc and Cdk6 over-expression in melanoma samples. Samples were 
assessed to be over-expressing (upreg) these genes if the expression level was 2-fold that 
of wild-type skin.   
ND = not done 
 
 
 
 
 
 
 
 
 
qRT-PCR Immunohistochemistry Sequence 
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